Back grey_arrow_rt.gif
 
Archived NATAP Articles from March 2002
 
null.gif
 
 
  1. Rosiglitazone In The Treatment of HAART-Associated Lipodystrophy: a randomized, double-blinded, placebo controlled study Written by Jules Levin (03/28/02)

    2.  
  2. Highlights of Treatment for HBV or HCV Coinfection Written for NATAP by Raymond Chung, MD, Director of Liver Transplantation Program, Massachusetts General Hospital (03/26/02)

    3.  
  3. HIV Resistance Andrew Zolopa, MD, Stanford University - (03/22/02)

    4.  
  4. Women with HIV: More conference time Written for NATAP by Judith Aberg, MD, Washington University, Director of HIV Clinic, St Louis (03/19/02)

    5.  
  5. Insulin Resistance, Glucose Intolerance: What does it all mean? Written for NATAP by Judith Aberg, Washington University, St Louis - (03/19/02)

    6.  
  6. Complications of HIV; HIV+ Not in Care or Being Tested - (03/19/02)

    7.  
  7. Maternal - Fetal Transmission at Retrovirus Written by Danielle Milano, MD, Boriken Family Health Services, New York - (03/18/02)

    8.  
  8. HCV Viral Kinetics Written by Nancy Shulman, MD, Stanford University, and Jules Levin - (03/18/02)

    9.  
  9. HIV and Women at Retrovirus Written for NATAP by Danielle Milano, MD, Boriken Family Health Services, NYC - (03/18/02)

    10.  
  10. Tattoo Risks for HCV - (03/18/02)

    11.  
  11. Tenofovir Resistance and its Role in Therapy - (03/14/02)

    12.  
  12. Hepatitis B and C Coinfection Report - Wriiten by Nancy Shulman, MD, Stanford University - (03/14/02)

    13.  
  13. Expanded Access Available for New Hepatitis B Drug- Adefovir - (03/14/02)

    14.  
  14. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy - (03/14/02)

    15.  
  15. T-20 and Beyond: Inhibition of HIV Attachment and Fusion at the 9th CROI - Reported by Christopher D. Pilcher, M.D. UNC at Chapel Hill Center for AIDS Research - (03/11/02)

    16.  
  16. PRIMARY HIV INFECTION-THE 'WINDOW OF OPPORTUNITY' - Reported by Christopher D. Pilcher, MD of the University of North Carolina at Chapel Hill Center for AIDS Research - (03/11/02)

    17.  
  17. Opportunistic Conditions in the HAART Era - David Alain Wohl, MD University of North Carolina AIDS treatment and Research Center - (03/11/02)

    18.  
  18. HIV and Cardiovascular Disease: True True or Unrelated? The Debate Continues - Reported by Judith Aberg, MD, Medical Director, HIV Services, washington University School of Medicine, St. Louis, and ACTG researcher - (03/11/02)

    19.  
  19. Structured Treatment Interruptions - Reported by Mike Youle, MD, Royal Free HIV Clinic, London, UK - (03/11/02)

    20.  
  20. Hepatitis B Report : More Acute HBV Infection in HIV-Patients; 3TC Protective; 14% Vaccinated - (03/11/02)

    21.  
  21. Tipranavir (new PI) Resistance Report - (03/11/02)

    22.  
  22. When To Begin Therapy: deferring therapy may reduce health and longevity - (03/11/02)

    23.  
  23. Pharmacogentics - (03/6/02)

    24.  
  24. Adherence to HIV Therapy - Helping the Medicine Go Down
    David Alain Wohl, MD - University of North Carolina AIDS Clinical Treatment and Research Center     (03/6/02)

    25.  
  25. Immunology
    Written by David Margolis, MD, University of Texas, Southwestern Medical Center, and ACTG researcher     (03/6/02)

    26.  
  26. Do Older Folks (>50) Progress More Quickly
    (03/3/02)

    27.  
  27. Attacking Lipodystrophy
    David Alain Wohl, MD - University of North Carolina AIDS Treatment and Research Center
    (03/3/02)

    28.  
  28. Switching Antiretroviral Therapy for Lipoatrophy
    David Alain Wohl, MD - University of North Carolina AIDS Treatment and Research Center
    (03/3/02)

    29.  
  29. IL-2 & HCV/HIV Coinfection
    (03/3/02)

    30.  
  30. Atazanavir+saquinavir once daily vs RTV/SQV twice daily
    (03/3/02)

    31.  
  31. New drugs: perhaps some genuine excitement this time
    Reported on the Retrovirus conference for NATAP by Graham Moyle, MD, M. B. B. S., Chelsea & Westminster Hospital, London, UK
    (03/3/02)

    32.  
  32. Risk of Death & Grade 4 events in HCV/HIV Coinfected
    (03/3/02)

    33.  
  33. Direct Observed Therapy In Methadone and Cocaine Users
    (03/3/02)

    34.  
  34. Switching from a Protease Inhibitor to Efavirenz, Nevirapine or Abacavir
    (03/3/02)

    35.  
  35. Hepatitis C Report from the Retrovirus Conference: report 1
    (03/1/02)

    36.  
  36. 9th Retrovirus Conference Highlights From Late Breakers
    (03/1/02)

    37.